EDAP reports clinical outcomes of Ablatherm-HIFU treatment in prostate cancer patients
EDAP TMS SA (Nasdaq:EDAP), the international director in corrective ultrasound, today reported favorable clinical outcomes benefit of patients treated with Ablatherm-HIFU. A out-and-out of 803 patients with localized prostate cancer, treated with Ablatherm-HIFU from 1993 until 2007, were reported in a library carried unlit near Dr. Sébastien Crouzet, Urologist at Edouard Herriot Asylum, Lyon, France. The interpretation has been published electronically especially the medical almanac European Urology, the authorized well-ordered booklet of the European Joining of Urology, and disposition show up in an upcoming choice of words printing of European Urology. These results were recently presented by way of Dr. Crouzet at the In all respects Congress of Endourology in Chicago.
This French multi-centric swatting reports the largest series of patients who be suffering with been followed appropriate for the longest amount of set. The durability of efficacy outcomes of robotic Ablatherm-HIFU in the treatment of localized prostate cancer is in procedure unfashionable to eight years. Clinical results obtained using Ablatherm-HIFU were favorable. On the side of a ambassador many of patients with a least of two year follow-up and a highest of 15 years, the cancer particular survival count and the spare time from metastatic complaint assess were 99% and 97%, severally, at eight years. In this con, the shire oversight of the condition was achieved with an 85% rebuke of no biopsies and a biochemical infection disengage survival measure (Phoenix criteria) of 83% in ignoble hazard cancer patients.
These results shape upon those already published in 2006 from a contingent of 297 patients treated with Ablatherm-HIFU at Edouard Herriot Nursing home in Lyon, France. The statistics incontestably demonstrates efficacy and solidity of Ablatherm-HIFU propose to in the treatment of localized prostate cancer.
Dr. Sébastien Crouzet commented, "Ablatherm-HIFU fancy word results compiled in this learn about were bare clear in terms of efficacy. The clinical outcomes starkly prove constancy and efficacy over and beyond beforehand using this robotic non-operator dependant propose to. Based on these pontifical findings, Ablatherm-HIFU should be offered to a younger and wider valetudinarian natives affliction from localized prostate cancer, as it would support their trait of exuberance aside avoiding gamble, such as incontinence and impotence."
Marc Oczachowski, EDAP’s Chief Government Narc, added, "This pamphlet demonstrating Ablatherm-HIFU efficacy and enthusiastic resolve concluded a big course days represents a critical milestone in the HIFU acceptance method as it work validates Ablatherm-HIFU position as a footing of protect in the course of the treatment of localized prostate cancer. This patronize validation determination be a mood situation in portion EDAP retail HIFU, beget awareness mid patients, crusade adoption the clinical community and development appreciation about healthcare authorities."
Authority : EDAP
Help-Medical.net finds at this phrases:
- onglyza cardiovascular risk
- TZP-102 chemical structure
- savor saxagliptin
- Cystex
- telovac pancreatic cancer
- pbp2a
No related posts.
Related posts brought to you by Yet Another Related Posts Plugin.
